Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 92.94% | 92.77% | -4.60% | -2.03% | -932.11% |
| Total Depreciation and Amortization | -45.73% | -44.42% | -17.45% | -19.47% | -9.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.16% | -101.18% | 13.35% | 15.50% | 5,147.44% |
| Change in Net Operating Assets | -- | -- | 97.78% | 92.92% | -- |
| Cash from Operations | -51.92% | -55.47% | 28.10% | 29.88% | 52.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -51.73% | -52.91% | -- |
| Cash from Investing | -- | -- | -51.73% | -52.91% | -- |
| Total Debt Issued | 26.10% | 26.10% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.08% | 29.04% | 25.96% | 22.86% | -- |
| Foreign Exchange rate Adjustments | -7.14% | -11.90% | -132.00% | -130.77% | -130.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -573.58% | -590.23% | 4,090.24% | 3,980.95% | 96.92% |